Axsome Therapeutics (AXSM) Q4 results: Revenues: $0; Net loss: ($24.8M) (-158.3%); loss/share: ($0.71) (-121.9%); Quick Assets: $220M.
Anticipated Milestones: NDA filings for AXS-05 in the treatment of MDD and AXS-07 for the treatment of migraine in Q4.
Topline results for Phase 3 STRIDE-1 trial of AXS-05 in TRD and Phase 3 INTERCEPT trial of AXS-07 in migraine on track for Q1.
Topline results for ADVANCE Phase 2/3 trial of AXS-05 in Alzheimer’s disease agitation anticipated in Q3.
Initiation of Phase 3 trial of AXS-12 in narcolepsy anticipated in H2.
Axsome plans to meet with the FDA in 2020 to
discuss the further clinical development of AXS-14 for the treatment of
fibromyalgia.
Shares are down 17% premarket.
Previously: Axsome Therapeutics EPS misses by $0.23 (March 12)
https://seekingalpha.com/news/3551012-axsome-therapeutics-down-17-premarket-on-q4-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.